PTO/SB/08 (2-92)
Sheet 1 of 1

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 342312000920	Application Number 09/235,771 09/641,396
Applicant: Mikhail F. GORDEEV, et al.	
Filing Date January 22, 1999	Group Art Unit 1614 1639

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	0.						

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	Translation NO
NB	1.	04/19/89	EP 0 312 000	Europe				
	2.	01/31/90	EP 0 352 781	Europe				
	3.	05/13/93	WO 93/09103	~~PCT~~ WIPO				
	4.	11/25/93	WO 93/23384	~~PCT~~ WIPO				
	5.	03/16/95	WO 95/07271	~~PCT~~ WIPO				
	6.	06/01/95	WO 95/14684	~~PCT~~ WIPO				
	7.	03/20/97	WO 97/10223	~~PCT~~ WIPO				
	8.	05/29/97	WO 97/19039	~~PCT~~ WIPO				
	9.	06/19/97	WO 97/21708	~~PCT~~ WIPO				
	10.	08/07/97	DE 196 49 095	Germany			Abstract	only
	11.	01/15/98	WO 98/01446	~~PCT~~ WIPO				
NB	12.	01/15/98	WO 98/01447	~~PCT~~ WIPO				

.OTHER DOCUMENTS *(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
NB	13.	Balkenhohl et al., (1996) " Combinatorial Synthesis of Small Organic Molecules," *Angewandte Chemie*. International Edition, vol. 35, no. 20, pages 2288-2237.
NB	14.	Buchstaller, H. (April 2, 1998) " Solid Phase Synthesis of Oxazolidinones via a Novel Cyclisation/ Cleavage Reaction," *Tetrahedron* vol. 54, no. 14, pages 3465-3470.
NB	15.	Holte, P. et al., (October 1,1998). Solid-Phase Synthesis of 3,5-Disubstituted 1,3-Oxazolidin-2-ones by an Activation/Cyclo-elimination Process," *Tetrahedron Letters*, vol. 39, no.40, pages 7407-7410.

EXAMINER: NB	DATE CONSIDERED: 2/5/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 342312000920	Application Number 09/235,771
Applicant: Gordeev et al.	
Filing Date January 22, 1999	Group Art Unit 1614

1634

jc873 U.S. PTO 09/641396 08/17/00

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	Translation NO
MR	27.	05/05/82	EP 0 050 827	Europe				
	28.	06/11/86	EP 0 184 170 A2	Europe				
	29.	09/07/88	EP 0 281 289 A1	Europe				
	30.	05/24/89	EP 0 316 594 A1	Europe				
	31.	03/21/90	EP 0 359 172 A1	Europe				
	32.	03/21/90	EP 0 359 418 A1	Europe				
	33.	01/24/96	EP 0 693 491 A1	Europe				
	34.	01/31/96	EP 0 694 543 A1	Europe				
	35.	01/31/96	EP 0 694 544 A1	Europe				
	36.	10/23/96	EP 0 738 726 A1	Europe				
	37.	07/23/97	EP 0 785 201 A1	Europe				
	38.	08/13/97	EP 0 789 026 A1	Europe				
	39.	11/17/92	JP 04-327580 A2	Japan				
	40.	02/13/86	WO 86/00991	~~PCT~~ WIPO				
	41.	05/30/91	WO 91/07409	~~PCT~~ WIPO				
	42.	05/09/96	WO 96/13502	~~PCT~~ WIPO				
	43.	03/13/97	WO 97/09328	~~PCT~~ WIPO				
	44.	05/29/97	WO 97/19089	~~PCT~~ WIPO				
	45.	07/31/97	WO 97/27188	~~PCT~~ WIPO				
	46.	08/28/97	WO 97/30981	~~PCT~~ WIPO				
	47.	08/28/97	WO 97/30995	~~PCT~~ WIPO				
MR	48.	09/04/97	WO 97/31917	~~PCT~~ WIPO				

OTHER DOCUMENTS *(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
MR	49.	Alasandro, M., "Separation of diastereoisomers of DuP 105, a novel oxazolidinone antibacterial agent, by supercritical fluid chromatography on a Chiralcel OD column"(1996) *J. Pharm. Biomed.* 14:807-814.

EXAMINER: MR DATE CONSIDERED: 2/5/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 342312000920	Application Number 09/235,771 04/644,346
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant Gordeev et al.	
(Use several sheets if necessary)	Filing Date January 22, 1999	Group Art Unit 1614 1639

OTHER DOCUMENTS *(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
MB	50.	Albert et al., "Comparison of *in vitro* trichomonacidal properties of some nitrofurans employed in therapeutics" (1973) *Ann. Pharm. Fr.* 31:57-62. (English translation abstract).
	51.	Augé et al., "Lithium trifluoromethanesulfonate-catalysed aminolysis of oxiranes" (1996) *Tetrahedron Letters* 37:7715-7716.
	52.	Barbachyn et al., "Potent Water Soluble Prodrugs of the Oxazolidine Antibacterial Agent Eperezolid", Poster F-23, 37th *Interscience Conference on Antimicrobial Agents and Chemotherepy,* Toronto, Canada, September 28 to October 01, 1997.
	53.	Barbachyn et al., "Synthesis and structure activity relationships of new tropone-substituted oxazolidinone antibacterial agents" (1995) *Abstracts of the 35th ICAAC Session 130. Poster Oxazolidinones.* p. 149. (Abstract F206).
	54.	Barbachyn et al., "Identification of new oxazolidinone antibacterial agents with potent *in vivo* antimycobacterial activity" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 152. (Abstract F227).
	55.	Barbachyn et al., "Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity" (1996) *J. Med. Chem.* 39:680-685.
	56.	Barry et al., "*In vitro* evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents" (1988) *Antimicrob. Agents Chemother.* 32:150-152.
	57.	Bartel et al., "Synthesis and Antibacterial Activity of Novel Hteroaryl Oxazolidinones I: Pyridyl Oxazolidinones",Poster F-017, 37th *Interscience Conference on Antimicrobial Agents and Chemotherepy,* Toronto, Canada, September 28 to October 01, 1997.
	58.	Bartel et al., "Synthesis and Antibacterial Activity of Novel Heteroaryl Oxazolidinones II: Pyridyl Oxazolidinones",Poster F-018, 37th *Interscience Conference on Antimicrobial Agents and Chemotherepy,* Toronto, Canada, September 28 to October 01, 1997.
	59.	Bartel et al., "Synthesis and Antibacterial Activity of Novel Heteroaryl Oxazolidinones III: Pyridyl Oxazolidinones",Poster F-019, 37th *Interscience Conference on Antimicrobial Agents and Chemotherepy,* Toronto, Canada, September 28 to October 01, 1997.
	60.	Batts et al., "U-100592 phase I, multiple-dose, randomized placebo-controlled, safety, tolerance and pharmacokinetics in healthy volunteers for 14.25 days using bulk drug in capsules" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 152. (Abstract F226).
MB	61.	Bostic et al., "Comparative *in vitro* and bactericidal activity of oxazolidinone antibiotics against multi-drug resistant enterococci" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 151. (Abstract F219).

EXAMINER: MB	DATE CONSIDERED: 2/5/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 342312000920	Application Number 09/235,771
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant	04/04/1346
(Use several sheets if necessary)	Gordeev et al.	
	Filing Date January 22, 1999	Group Art Unit 1634

OTHER DOCUMENTS *(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	62.	Brickner et al., "Synthesis of U-100592 and U-100766, two new oxazolidinone antibacterial agents in clinical trials for treatment of multiply resistant gram positive infections" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 149. (Abstract F208).
	63.	Brickner et al., Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections" (1996) *J. Med. Chem.* 39:673-679.
	64.	Brickner et al., "Oxazolidinone antibacterial agents" (1996) *Curr. Pharm. Des.* 2:175-194.
	65.	Brumfitt et al., "*In-vitro* microbiological activities of DuP 105 and DuP 721, novel synthetic oxazolidinones" (1988) *J. Antimicrob. Chemother.* 21:711-720.
	66.	Brumfitt et al., "Antibacterial oxazolidinones: *In vitro* activity of a new analogue, E3709" (1992) *Diagn. Microbiol. Infect. Dis.* 15:621-625.
	67.	Bush et al., "Kinetic interactions of tazobactam with β-lactamases from all major structural classes" (1993) *Antimicrobial Agents and Chemotherapy* 37:851-858.
	68.	Canonne et al.. "Synthesis of Chiral 3-Substituted 2,4(1H,3H)-Quinazolinediones" (1993), *Heterocycles*, 36:1305-1314
	69.	Daly et al., "Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds" (1988) *J. Antimicrob. Chemother.* 21:721-730.
	70.	Daub et al., "Isolation, cloning, and sequencing of the *salmonella typhimurium ddlA* gene with purification and characterization of its product, D-alanine:D-alanine ligase (ADP forming)" (1989) *Biochemistry* 27:3701-3708.
	71.	Dellaria et al., "Optimization and *in vivo* evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacement" (1987) *J. Med. Chem.* 30:2137-2144.
	72.	Demyan et al., "The Oxazolidinone Linezolid Inhibits Translation Initiation in Bacteria", Poster C-102, 37th *Interscience Conference on Antimicrobial Agents and Chemotherepy,* Toronto, Canada, September 28 to October 01, 1997.
	73.	Denis et al., "5-aryl-β,γ butenolide, a new class of antibacterial derived from the n-aryl oxazolidinone DUP 721" (1994) *Bioorg. & Med. Chem. Lett.* 4:1925-1930.
	74.	de Parrodi et al., "Preparation of enantiomerically pure *cis-* and *trans-N-*(propionyl)hexahydrobenzoxazolidin-2-ones" (1997) *Tetrahedron: Asymmetry* 8:1075-1082.
	75.	Ding et al., "Transformation of heterocyclic reversible monoamine oxidase-B inactivators into irreversible inactivators by *N*-methylation" (1993) *J. Med. Chem.* 36:3606-3610.

EXAMINER:	DATE CONSIDERED: 2/6/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 342312000920	Application Number 09/235,771
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant	04/04/1946
(Use several sheets if necessary)	Gordeev et al.	
	Filing Date January 22, 1999	Group Art Unit 1614 1679

OTHER DOCUMENTS *(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
MR	76.	Eliopoulos et al., "Activities of the new oxazolidinone antimicrobials against enterococci" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 151. (Abstract F217).
	77.	Ford et al., "*In vivo* efficacy evaluations of U-100592 and U-100766, new oxazolidinone antibiotics" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 151. (Abstract F221).
	78.	Ford et al., "Oxazolidinones: new antibacterial agents", (1997) *Trends in Microbiology*, 5:196-200.
	79.	Frost et al., "Antibacterial activity of 3-(1-methyl-5-nitro-2-imidazolylmethylideneamino)-2-oxazolidinone" (1975) *J. Appl. Bacteriol.* 38:177-184.
	80.	Gadwood et al., "Synthesis of Oxazolidinone Antibacterial Agents Incorporating Morpholine and Piperazine N-Oxides: Oxazolidinone Prodrugs having High Water Solubility", Poster F-20, 37th *Interscience Conference on Antimicrobial Agents and Chemotherepy,* Toronto, Canada, September 28 to October 01, 1997.
	81.	Gates et al., "5-(Aminomethyl)-3-aryl-2-oxazolidinones. A Novel Class of Mechanism – Based Inactivators of Monoamine Oxidase B", (1990) *J. Am. Chem. Soc.*, 112:9364-9372
	82.	Getman et al., "Discovery of a novel class of potent HIV-1 protease inhibitors containing the (*R*)-(hydroxyethyl) urea isostere" (1993) *J. Med. Chem.* 36:288-291.
	83.	Geysen et al., "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid" (1984) *Proc. Natl. Acad. Sci. USA* 81:3998-4002.
	84.	Gleave et al., "Oxazolidinone antibacterial agents. An enantioselective synthesis of the [6,5,5] tricyclic fused oxazolidinone ring system and application to the synthesis of a rigid DuP 721 analogue" (1996) *J. Org. Chem.* 61:6470-6474.
	85.	Gordon et al., "Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions" (1994) *J. Med. Chem.* 37:1385-1401.
	86.	Grega et al., "Regioselective metalation of phoroanilines. An application to the synthesis of fluorinated oxazolidinone antibacterial agents" (1995) *J. Org. Chem.* 60:5255-5261.
	87.	Gregory et al., "Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 2. The "A" group" (1990) *J. Med. Chem.* 33:2569-2578.
	88.	Gregory et al., "Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 1. The "B" group" (1989) *J. Med. Chem.* 32:1673-1681.
MR	89.	Gualerzi et al., "Initiation of mRNA Translation in Prokaryotes", (1990) *Biochemistry*: 29:5881-5889.

EXAMINER: MR	DATE CONSIDERED: 2/5/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 342312000920	Application Number 09/235,771 04/644,396
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant	Gordeev et al.
(Use several sheets if necessary)	Filing Date January 22, 1999	Group Art Unit 1614 1639

OTHER DOCUMENTS *(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
MB	90.	Hermkens et al., "Solid-phase organic reactions: A review of the recent literature" (1996) *Tetrahedron* 52:4527-4554.
	91.	Houghten et al., "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery" (1991) *Nature* 354:84-86.
	92.	Howard et al., Preliminary pharmacokinetic and metabolic study of U-100480, a substituted oxazolidinone antibiotic, in the rat" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 153. (Abstract F230).
	93.	Hutchins et al., "A general method for the solid phase synthesis of ureas" (1994) *Tetrahedron Lett.* 35:4055-4058.
	94.	Hutchinson et al., "Piperazinyl oxazolidinones: Structure activity relationships of a new class of oxazolidinone antibacterial agents" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 149. (Abstract F207).
	95.	Hutchinson et al., "Structure-activity relationships of piperazinylphenyl oxazolidinone antibacterial agents and related developments" (1996) Book of Abstracts, 212th ACS National Meeting, Orlando, FL.,August 25-29. American Chemical Society, Washington, D.C., Publisher.
	96.	Ishii et al. "Highly Selective Aldose Reductase Inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic Acids", (1996), 39:1224-1927
	97.	Jenkins et al., "Comparative *in vitro* activities of vancomycin and the oxazolidinones U-100592 and U100766 against 300 clinical staphylococcal isolates" (1995) *Abstracts of the 35th ICAAC Session 130. Poster Oxazolidinones.* p. 150. (Abstract F213).
	98.	Jones et al., "*In vitro* spectrum and activity of U-100592 and U-100766, two novel oxazolidinones" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 149. (Abstract F209).
	99.	Kaatz et al., "*In vitro* activity of oxazolidinone compounds U100592 (592) and U100766 (766) versus *staphylococcus aureus* (SA) and *staphylococcus epidermis* (SE)" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 150. (Abstract F215).
	100.	Kalnbergs et al., "Synthesition reactions of carbEnesic hydrocarbons. New derivatives of diazabenzanthracene and triazaphenalene.ang." (1967) *Khim.-Farm. Zh.* 1:47-49. (English translation abstract).
	101.	Kick et al., "Expedient method for the solid-phase synthesis of aspartic acid protease inhibitors directed toward the generation of libraries" (1995) *J. Med. Chem.* 38:1427-1430.
MB	102.	Klemens et al., "Activities of the two novel oxazolidinones against M. tuberculosis (MTB) in a murine model" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 152. (Abstract F228).

EXAMINER: MB	DATE CONSIDERED: 2/5/08

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 342312000920	Application Number 09/235,171
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant	Gordeev et al.
(Use several sheets if necessary)	Filing Date January 22, 1999	Group Art Unit 1614

OTHER DOCUMENTS *(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
NB	103.	Koike et al., "Drug safety studies with a novel oxazolidinone, U-100766" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 152. (Abstract F224).
	104.	Lam et al., "A new type of synthetic peptide library for identifying ligand-binding activity" (1991) *Nature* 354:82-84.
	105.	Lizondo et al., "Linezolid. Oxazolidinone antibacterial. U-100766" (1996) *Drugs of the Future* 21:1116-1123.
	106.	Lowe et al., "Structure-Activity Relationship of Quinazolinedione Inhibitors of Calcium-Independent Phosphodieterase" (1991) *J. Med. Chem.* 34:623-628.
	107.	Luly et al., "New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the P_1 site" (1988) *J. Med. Chem.* 31:532-539.
	108.	Luly et al., "New inhibitors of human renin that contain novel Leu-Val replacements" (1987) *J. Med. Chem.* 30:1609-1616.
	109.	March, "Double and triple covalent bonds" *Advanced Organic Chemistry,* 3d Edition, pp. 16-17, Wiley-Interscience, New York.
	110.	Manninen et al., "Investigation into the metal ion dependency of the regiospecific alkylation/cyclization reaction producing 5-(*R*)-hydroxymethyl-3-aryl-oxazolidinones" (1996) Book of Abstracts, 212th ACS National Meeting, Orlando, FL, August 25-29. American Chemical Society, Washington, D.C., Publisher.
	111.	Martin et al., "The metabolism and kinetics of a novel oxazolidinone, U-100592" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 151. (Abstract F221).
	112.	Mason, Jr. et al., "Activity of oxazolidinones U-100592 and U-100766 *in vitro* against penicillin-resistant and cephalosporin-resistant strains of *S. pneumoniae*" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 150. (Abstract F212).
	113.	Merrifield, R.B., "Solid phase peptide synthesis. 1. The synthesis of a tetrapeptide" (1963) *J. Am. Chem. Soc.* 85:2149-2154.
	114.	Montginoul et al., "Activities analgesiques, anticonvulsivates et anti-inflammatories de 1H, 3H-quinazolinediones-2,4", (1988), *Ann Pharmaceutiques Francaises,* 46:223-232. (English translation abstract).
	115.	Moureau et al., "A reversible monoamine oxidase inhibitor toloxatone: structural and elecronic properties", (1992) *Eur J Med Chem,* 27:939-948.
NB	116.	Mulazimoglu et al., "*In vitro* activity of two novel oxazolidinones (U100592 and U10076), a new fluoroquinolone (CP-99219,27), and a streptogramin (Synercid) against *S. aureus* and *S. epidermidis*" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 149. (Abstract F210).

EXAMINER:	DATE CONSIDERED: 7/5/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 342312000920	Application Number 09/235,771
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant	Gordeev et al.
(Use several sheets if necessary)	Filing Date January 22, 1999	Group Art Unit 1614

OTHER DOCUMENTS *(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	117.	Neu et al., "*In vitro* activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105" (1988) *Antimicrob. Agents Chemother.* 32:580-583.
	118.	Park et al., "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 4 Multiply-Substituted Aryl Derivitives" (1992) *J. Med. Chem.*, 35:1156-1165.
	119.	Pawsey et al., "1st administration of a new oxazolidinone antibiotic (U-100592) to man" *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 152. (Abstract F225).
	120.	Piper et al., "Drug safety evaluation of U-100592, and oxazolidinone antibiotic, in dogs and rats" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 152. (Abstract F223).
	121.	Poel et al., "Novel Phenyloxazolidinone Antibacterial Agents Containing Saturated and 4,5-Unsaturated 4-Pyridinyl and Thiopyranyl Aryl Substituents", Pharmacia & Upjohn
	122.	Ranaldi et al., "Transport of the antibacterial agent oxazolidin-2-one and derivatives across intestinal (Caco-2) and renal (MDCK) epithelial cell lines" (1996) *Antimicrob. Agents Chemother.* 40:652-658.
	123.	Reisch et al., " Alkylation of Quinazoline-2,4 (1 *H*, 3*H*)-diones with 1,4-Dibromo-2-methylbut-2-methylbut-2-ene under Phase-Transfer-Catalysis" *J. Heterocyclic Chem.*, (1993) 30:1117-1120.
	124.	Rich et al., "Preparation of a new *o*-nitrobenzyl resin for solid-phase synthesis of *tert*-butyloxycarbonyl-protected peptide acids" (1975) *J. Am. Chem. Soc.* 97:1575-1579.
	125.	Rotella, D.P., "Solid phase synthesis of olefin and hydroxyethylene peptidomimetics" (1996) *J. Am. Chem. Soc.* 118:12246-12247.
	126.	Rybak et al., "Comparative *in vitro* activity of oxazolidinone compounds U100592 (592) and U100766 (766) versus vancomycin (V) against *staphylococcus aureus* and coagulase-negative staphylococci" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 150. (Abstract F211).
	127.	Schaus et al., "Dynamic kinetic resolution of epichlorohydrin via enantioselective catalytic ring opening with $TMSN_3$. Practical synthesis of aryl oxazolidinone antibacterial agents" (1996) *Tetrahedron Letters* 37:7937-7940.
	128.	Seneci et al., "Synthesis and Antimicrobial Activity of Oxazolidin-2-ones and Related Heterocycles", (1994) *J. Chem. Soc. Perkin Trans.*, 1:2345-2351.
	129.	Silverman et al., "The oxazolidinone antibacterial agent DuP 105 does not act on cell wall biosynthesis or on a β-lactamase" (1993) *Biochem. Biophys. Res. Comm.* 195:1077-1080.

EXAMINER:	DATE CONSIDERED: 2/5/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 342312000920	Application Number 09/233,771
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant Gordeev et al.	
(Use several sheets if necessary)	Filing Date January 22, 1999	Group Art Unit 1614 1634

OTHER DOCUMENTS *(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	130.	Spangler et al., "Susceptibility of 115 penicillin susceptible and resistant pneumococci to two oxazolidinones compared to penicillin G, ceftriaxone, telcoplanin, vancomycin, rifampin and imipenem" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 151. (Abstract F218).
	131.	Ulanowicz et al., "Synthesis and Biological Activity of N-Acetyl Modified Analogs Of Oxazolidinone Antibacterial Agents Linezolid and Eperezolid", Poster F-21, 37th *Interscience Conference on Antimicrobial Agents and Chemotherepy,* Toronto, Canada, September 28 to October 01, 1997.
	132.	"Upjohn oxazolidinone antibacterial agents" *Posters Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy* San Francisco, 17-20 September 1995.
	133.	Van Delft et al., "Preparation of 2-oxazolidinones by intramolecular nucleophilic substitution" (1997) *Synthesis* 450-454.
	134.	Wang et al., "Solid phase synthesis of protected peptides via photolytic cleavage of the α-methylphenacyl ester anchoring linkage" (1976) *J. Org. Chem.* 41:3258-3261.
	135.	Wang et al., "Chiral synthesis of DuP 721, a new antibacterial agent" (1989) *Tetrahedron* 45:1323-1326.
	136.	Watts et al., "*In vitro* activity of two oxazolidinone antimicrobial agents (U-100592 and U-100766) against *Mycoplasma* spp." (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 151. (Abstract F220).
	137.	Zamkoff et al., "Activity of U-100480, an oxazolidinone, against M. avium complex (MAC) infection in beige mice" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 153. (Abstract F229).
	138.	Zurenko et al., "*In vitro* antibacterial activity of U-100592 and U-100766, novel oxazolidinone antibiotics" (1995) *Abstracts of the 35th ICAAC Session 130. Poster. Oxazolidinones.* p. 150. (Abstract F216).
	139.	Zurenko et al., "Oxazolidinone antibacterial agents: development of the clinical candidates eperezolid and linezolid" (1997) *Expert Opin. Invest. Drugs* 6:151-158.
	140.	Zurenko et al., "*In vitro* activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents" (1996) *Antimicrob. Agents Chemother.* 40:839-845.
	141.	Grant (1992) *Synthetic Peptides. A User's Guide*, W.H. Freeman and Co., table of contents enclosed herein.
	142.	Greene *et al. Protective Groups in Organic Synthesis*, 2nd Ed. (John Wiley & Sons, Inc., New York), table of contents enclosed herein.

EXAMINER: _____ DATE CONSIDERED: 2/5/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.